Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Everolimus and imatinib mesylate may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth. Everolimus may also block blood flow to the
tumor. Giving everolimus together with imatinib mesylate may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving everolimus together with imatinib
mesylate works in treating patients with metastatic or unresectable kidney cancer.